Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

KEYNOTE-183 Investigators

Research output: Contribution to journalArticlepeer-review

101 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences